CDK4/6 Inhibitor Drugs Market size is estimated to cross USD 66.63 Billion by the end of 2035, expanding around 16.78% CAGR during the forecast period i.e., 2023-2035. In the year 2022, the industry size of CDK4/6 inhibitor drugs was over USD 9.03 Billion. According to Breastcancer.org, breast cancer is the most common cancer in the world, accounting for 12.5% of new cancer cases worldwide each year. The increasing prevalence of breast cancer is a major driver of the CDK-4/6 inhibitor market. CDK4/6 inhibitors are effective in treating hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer, making them a valuable treatment option. As the incidence of breast cancer continues to increase worldwide, the demand for targeted and effective treatments such as CDK-4/6 inhibitors is increasing, contributing to market expansion.
As health spending increases, funding for research and development activities typically increases proportionately. Investment in innovative cancer treatments, coupled with increasing awareness of the effectiveness of these inhibitors, is contributing to their acceptance and market growth. Financial commitment to medical infrastructure and research will further accelerate the development and access of CDK4/6 inhibitors to cancer patients. The global CDK-4/6 inhibitors market is expected to witness strong growth during the forecast period. This is because medical costs per person are high.
Growth Driver
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
16.78% |
|
Base Year Market Size (2022) |
USD 9.03 Billion |
|
Forecast Year Market Size (2035) |
USD 66.63 Billion |
|
Regional Scope |
|
End User (Hospital, Clinics, Research Laboratories, Retail Pharmacies)
In terms end user segmentation, the hospital segment in the CDK4/6 inhibitor drugs market is anticipated to surpass USD 38.18 billion by the end of 2035. As the incidence of breast cancer increases, hospitals hold the highest market share. In the case of cancer, we have a higher influx of patients than other medical institutions because we have cutting-edge treatment technology. Therefore, the demand for this drug is highest in the hospital end-use sector. Additionally, intensified efforts by governments to build a strong healthcare framework in hospitals across the countries is also expected to boost the market. Additionally, the increasing number of surgical hospitals with single specialty expertise is also contributing to the market growth.
Patient (PreMenopause, PostMenopausal)
CDK4/6 inhibitor drugs market size from the post-menopausal segment is set to cross USD 56.20 billion by the end of 2035. The majority of breast cancers in postmenopausal women are hormonal receptor-positive, and breast cancer is most common in these women. Women's breast fat cells tend to produce increasing levels of the enzyme aromatase as they become older. The enzyme aromatase promotes the synthesis of estrogen. Consequently, as women age, their breasts contain an increased quantity of oestrogen. Postmenopausal women's breast cancer growth and expansion are both influenced by this locally generated oestrogen. Palbociclib is used in conjunction with an aromatase inhibitor to treat postmenopausal women and men with hormone-receptor-positive, HER2-negative, advanced-stage or metastatic breast cancer that has not previously received hormonal therapy.
Our in-depth analysis of the global CDK4/6 inhibitor drugs market includes the following segments:
|
Drug Type |
|
|
Patient |
|
|
End User |
|
North American Market Forecasts
The CDK4/6 inhibitor drugs market in the North America region is estimated to reach USD 45.96 billion by the end of the forecast period. Increasing number of clinical trials in the region is also driving market growth. The NCI-sponsored TAILORx clinical trial focused on patients with ER-positive, node-negative breast cancer and found that a test that looks at the expression of certain genes can predict which women can safely avoid chemotherapy. Other studies, such as RxPONDER, have found that some postmenopausal women with HER-2-negative, HR-positive breast cancer that has spread to multiple lymph nodes and has a low risk of recurrence do not benefit from chemotherapy. As a result, the demand for targeted therapies has increased significantly in the United States.
European Market Statistics
The CDK4/6 inhibitor drugs market in the Europe region is anticipated to grow significantly by registering a growth of USD 10.76 billion by the end of 2035. The European CDK-4/6 inhibitors market is growing significantly due to increasing government initiatives in major European countries such as the UK, Germany, Spain, and France. Additionally, the increasing prevalence of breast cancer has increased the use of advanced treatments and drugs, which is also one of the key factors driving the growth of the CDK-4/6 inhibitors market. Breast cancer accounts for 13.3% of all new cancer cases and is estimated to affect 1 in 11 of 74-year-old women in the EU.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?